Sascha Dublin’s main interest is studying the impact of therapeutic interventions, including medications, using real-world observational data. Through this work she aims to provide patients and health care providers with better information about the risks and benefits of different treatment options so they can make more informed decisions. Her work includes studies of medication use in relation to pneumonia risk and dementia risk in older adults. She seeks to improve the methods used to study drug safety in older adults by exploring biases that may arise when observational studies do not take into account coexisting illnesses and functional and cognitive status.
Dr. Dublin’s research also focuses on the outcomes of common interventions in pregnancy, including elective induction of labor (that is, bringing on labor when there is not a medical or obstetrical reason for immediate delivery). Her goal is to take advantage of the rich clinical data that are becoming increasingly available through electronic medical records to develop new knowledge and improve care. Dr. Dublin holds an R01 grant from the National Institute of Child Health and Human Development to study maternal and infant outcomes after elective induction of labor at term gestation. She is also the Group Health site principal investigator for the Medication Exposure in Pregnancy Risk Evaluation Program funded by the Food and Drug Administration (FDA).
Dr. Dublin’s methodological interests include epidemiologic methods, such as case-control studies and techniques to measure and control for potential confounding factors. She has experience with two-phase study designs and has led methods-focused workgroups for the FDA’s Mini-Sentinel Initiative. She is also interested in novel methods to extract information from clinical records, such as natural language processing.
Dr. Dublin collaborates with the Group Health Research Institute (GHRI)’s aging and immunization research teams, and her experience includes work with the Cardiovascular Health Research Unit, a joint division of GHRI and the University of Washington. She previously held a five-year Paul B. Beeson Career Development Award in Aging Research. She is a board-certified general internist who sees patients one day a week in primary care at Group Health.
Paul KJ, Walker RL, Dublin S.Anticholinergic medications and risk of community-acquired pneumonia in elderly adults: a population-based case-control study.
J Am Geriatr Soc. 2015 Mar 2. doi: 10.1111/jgs.13327. [Epub ahead of print].
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane P, Larson EB.Cumulative use of strong anticholinergic medications and incident dementia.
JAMA Int Med. 2015 Jan 26. doi: 10.1001/jamainternmed.2014.7663. [Epub ahead of print].
Thacker EL, Jensen PN, Psaty BM, McKnight B, Longstreth WT Jr, Dublin S, Newton KM, Smith NL, Siscovick DS, Heckbert SR.Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation.
Ann Pharmacother. 2015;49:378-386. DOI: 10.1177/1060028014568447. PII: 1060028014568447. PubMed
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Yu O, Crane PK, Larson EB.Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.
JAMA Intern Med. 2015 Jan 26. doi: 10.1001/jamainternmed.2014.7663. [Epub ahead of print].
Study coauthors Drs. Sascha Dublin, Shelly Gray, and Eric B. Larson explore how to balance the risks and benefits of these common medications.
March 2, 2015—Group Health study suggests higher risk with acute or chronic use
HealthDay (syndicated), Mar. 3, 2015